Dislipidemias em portadores de HIV/aids em uso de terapia antirretroviral

• Autor(a) principal: Nery, Max Weyler
• Data de Publicação: 2007
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• dARK ID: ark:/38995/0013000003j6s
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/7787
• topic: HIV; Aids; Dislipidemia; Terapia antirretroviral; Estudos transversais; Dyslipidemia; Antiretroviral therapy; Cross-sectional studies; SAUDE COLETIVA::EPIDEMIOLOGIA

Background: in a decade of highly active antiretroviral therapy (HAART), morbidity and mortaliy of aids remarkable decreased, however prolonged treatment has been associated with adverse effects, mainly metabolic abnormalities. Objective: to determine the prevalence and risk factors for dyslipidemia among patients on HAART, in Goiânia-Goiás-Brazil. Methods: a cross-sectional study was conducted in adults on HAART, during 2005 and 2006. Patients were interviewed; their medical and laboratory records abstracted and blood obtained for lipid measurements. Dyslipidemia was defined as CT  240 mg/dL, LDL  160 mg/dL, TG > 200 and/or HDL < 40 mg/dL. Case-control approach and multiple logistic regression analysis were applied (SPSS 11.0). Protocol was approved by Ethical Committee of Federal University of Goiás. Results: 113 patients were recruited; mean age 39.3; 68.1% males; 51.9% with undetectable HIV-1 viral load; 42.4% with CD4 + > 350 cel/mL. Half (50.4%) of them were on nucleoside reverse transcriptase inhibitors (NTRIs) plus non-nucleoside reverse transcriptase inhibitors (NNTRIs); 42.5% were on NTRI plus protease inhibitors (PIs). Prevalence of dyslipidemia was 66.7%, being HDL<40mg/dL (53.5%) the most frequent abnormally, followed by TG > 200 mg/dL (36.1%). Patients on PIs based regimen showed a 5.2 higher risk (CI95% 1.8-14.8) of dyslipidemia after adjusting by gender, age and HIV/aids disease onset. Conclusion: disclosed a high prevalence of dyslipemia and point out for interventions programs to reduce future cardiovascular events.